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Objective To identify the effect of serial casting combined with Botulinum toxin type A (BTX-A) injection on 
spastic equinus foot.
Method Twenty-nine children with cerebral palsy who had equinus foot were recruited from the outpatient clinic 
of Rehabilitation Medicine. The children were divided into 2 groups, one of which received serial casting after 
BTX-A injection, and the other which only received BTX-A injection. Serial casting started 3 weeks after the BTX-A 
injection, and was changed weekly for 3 times. Spasticity of the ankle joint was evaluated using the modified 
Ashworth scale (MAS), and the modifi  ed Tardieu scale (MTS). Gait pattern was measured using the physician’s 
rating scale (PRS).
Results Th   e degree of ankle dorsifl  exion and the MAS improved signifi  cantly until 12 weeks following the BTX-A 
injection in the serial casting group (p<0.001), while the BTX-A injection-only group improved until 6 weeks 
following injection (p<0.05). The combined group showed a significantly greater increase in the degree of 
dorsifl  exion compared to the BTX-A injection-only group at post-injection weeks 6 and 12 (p<0.05). Th  ree  children 
(11.5%) suff  ered from foot ulcers as a complication caused by the serial casting.
Conclusion Our study demonstrated that the eff  ect of BTX-A injection with serial casting was superior and lasted 
longer than the effect of BTX-A injection only in patients with spastic equinus foot. We therefore recommend 
BTX-A injection with serial casting for the treatment of equinus foot. However, physicians must also consider the 
possible complications associated with serial casting. 
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INTRODUCTION
  Equinus foot is a musculoskeletal complication often 
seen in patients with cerebral palsy and may cause 
limitation of activities such as the walking function.
1,2 
Equinus foot can be treated through physical therapy, 
such as stretching and muscle strengthening exercises, by 
antispastic drugs, BTX-A injection, ankle-foot orthoses Botulinum Toxin Type A Injection with Serial Casting
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and serial casting, or by surgery, such as archilles tendon 
elongation. Among these treatments, BTX-A injection 
and serial casting have minimum side eff  ects compared 
to drug therapy, which may cause CNS-related side 
eff  ects, such as cognitive disorders and sleepiness. Also, 
BTX-A injection and serial casting are localized and 
reversible treatments compared to surgery.
3
  Botulinum toxin type A is widely used to treat equinus 
foot by acting on acetylcholine receptors in the neuro-
muscular junction. The toxin irreversibly inhibits the 
release of acetylcholine from the pre-synaptic membrane 
and paralyzes muscles by blocking the neurotransmission 
pathway.
4 Two to three days after the BTX-A injection, 
spasticity is reduced; maximum effects occur in the 
second week, and the eff  ect continues for 3 to 6 months.
3,4 
Short leg casts are used to treat eqinus foot deformity 
by maintaining a long-term tonic stretch in muscles to 
increase elasticity in muscle-ligaments parts, and to 
increase the number of sarcolemma in muscle fibers.
5 
Various studies regarding the use of BTX-A injection 
followed by serial casting for treatment of spastic equinus 
foot have been published abroad.
6-17 However, casting 
after injection is not yet widely used in Korea, therefore 
further studies on clinical outcomes and side eff  ects are 
needed. This study aimed to determine the effects and 
complications caused by BTX-A injection followed by 
serial casting.
MATERIALS AND METHODS
Participants
  Patients who met the following criteria participated 
in the study: 1) children with spastic cerebral palsy in 
the Asan Medical Center, Department of Rehabilitation 
Medicine 2) admitted from November 2008 to March 
2009, and from November 2009 to February 2010 3) able 
to walk on their own 4) equinus gait (toe walking) 5) no 
record of surgery or BTX-A injection in recent 12 months. 
Patients incapable of walking, children with dyskinetic 
type, such as athetoid and ataxic type, or those who have 
skin problems due to casting could not participate in this 
study.
Methods
  After the process was explained to the parents/caretakers 
and was approved by them, children who received the 
BTX-A injection and were eligible to participate in the 
study received casting. Patients who received BTX-A 
injection only and had a similar ankle joint angle, 
spasticity, and gait pattern with children who received 
casting, were chosen for the injection only group. The 
patients participating in the study were divided into 2 
groups: 1) patients in the injection with casting group 
received BTX-A injection followed by casting 2) patients 
in the injection group only received BTX-A injection.
  To assess patients’ motor function, a Gross motor 
function classification system (GMFCS), Gross motor 
function measure (GMFM), and a Functional mobility 
scale (FMS) were used.
  For BTX-A injection, Dysport
® (Ipsen, Wrexham, United 
Kingdom) was used, and 1 doctor in the department of 
rehabilitation medicine conducted the study. Th  e  doctor 
decided the injection site to be in the medial and lateral 
gastrocnemius muscles after examination, and 12 to 18 
IU/kg of BTX-A was injected, depending on a patient’s 
weight.
  Three weeks after BTX-A injection, patients received 
their first short leg casting using the Fibrograss walking 
cast (NEAL CAST
®, BLTEH, Chuncheon, Korea). Th  is  was 
done weekly for 3 weeks. Th   e ankle joint angle, spasticity, 
and skin condition were assessed every time. Fibergrass 
walking casts were applied with the ankle in maximal 
passive dorsifl  exion (Fig. 1). Short leg casting was applied 
by 1 experienced physical therapist.
  Both the injection and cast group, and the injection 
only group received physical therapy including ankle 
stretching before and after injection, once per week, 
for 30 minutes, for 12 weeks. However, patients in the 
injection and cast group could not perform dorsifl  exion 
exercises while they were in their casts for 3 weeks, but 
rather performed weight bearing exercises.
  Th  e  eff  ect of the treatment was assessed by measuring 
changes in the degree of spasticity and gait pattern, 
before, 3, 6, and 12 weeks after treatment. Th   e change in 
the degree of ankle joint spasticity was measured using 
the Modified Ashworth scale (MAS) and the Modified 
Tardieu scale (MTS). In MTS, R1 is defined as the joint 
angle after fast stretch, and R2, the maximum joint angle 
after slow stretch.
18 The difference between R1 and R2, 
defined as the dynamic component (R2-R1), is used to 
assess spasticity after motor point blocks in children with 
cerebral palsy.
19 To compare soleus and gastrocnemius Sook Joung Lee, et al.
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muscles, we measured R1 and R2 of ankle joints when 
knees were bent and straightened. 
  Physician’s rating scale (PRS) was used for quantitative 
assessment of patients’ gait pattern.
20 PRS consists of 6 
categories including gait pattern, ankle position during 
stance, foot position during heel strike, knee joint angle 
during stance, shoulder angle when walking, and walking 
speed. Each category is rated from 0 to 3, and the total 
score ranges from 0 to 14 points. Th   e higher the score, the 
more mature and stable the gait pattern.
  To determine if the treatment had side eff  ects, such as 
a reduction in thigh muscles and pressure ulcers, thigh 
measurements were taken and patients were checked for 
skin problems.
  SPSS 14.0 for Windows was used for statistical analysis. 
The Friedman test was used to determine the changes 
before and after treatment, and the Mann-Whitney U 
test was used to compare the eff  ectiveness of treatments 
in the 2 groups. Th   e level for statistical signifi  cance was 
p-value less than 0.05, and Bonferroni was used as a post 
hoc test. Each category was paired and the Wilcoxon 
signed-rank test was performed 6 times; before injection, 
after injection, and 3, 6, and 12 weeks after injection. Th  e 
level for statistical significance in the post hoc test was 
0.05/6≒0.0083.
RESULTS
  Over 9 months, a total number of 86 patients received 
BTX-A injection, and 72 of them were eligible to 
participate in the study. The procedure of serial casting 
was explained to parents/caretakers, and when they 
provided consent, 26 patients were enrolled into an 
injection with casting group, and received serial casting, 
and 17 other patients who showed similar ankle joint 
angle and spasticity were enrolled into an injection only 
group. Follow-up was not possible for 5 patients from the 
injection only group, and 6 patients from the injection 
with casting group. Also, 3 patients from the injection 
with casting group suffered pressure ulcers during the 
serial casting procedure and had to stop treatment.
  Follow-up assessments were made, when possible, for a 
period of 12 weeks. Twelve patients (8 males, 4 females) 
from the injection only group and 17 patients (13 males, 
Fig. 1. Serial casting (A) A layer of stockinette was applied over foot and calf. (B) 
Cotton roll was applied. (C) Fibergrass walking cast (NEAL CAST
®, BLTEH, Korea) 
was applied with the ankle in maximal passive dorsifl  exion. Botulinum Toxin Type A Injection with Serial Casting
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4 females) from the injection with casting group were 
assessed. There were no significant difference in their 
motor functions regarding cerebral palsy, degree of 
spasticity, or the amount of BTX-A injected (Tables 1, 
2). No patients showed symptoms of fever, seizure or 
anaphylaxis.
  Change in ankle joint spasticity was determined in the 2 
groups (Tables 3, 4). Th   e MTS scale in the injection with 
casting group improved until 12 weeks after injection 
and was statistically significant. In the injection only 
group, conditions improved until 6 weeks after injection, 
but the treatment appeared less eff  ective after 12 weeks. 
R2-R1, defined as the dynamic component, decreased 
for 3 weeks after injection, but increased on the sixth 
week after casting (Fig. 2). R1 increased during the time 
periods before and 3 weeks after injection, whereas R2 
increased more than R1 when patients received casting 
from week 3 to week 6. In the injection only group, the 
dynamic component decreased until week 6, and the 
Table 1. General Characteristics of Subjects
Injection with
casting group 
(n=17)
Injection 
only group 
(n=12)
p-value
Age (yr) 5.8±2.9 4.3±1.7 0.482
Gender (number) 
Male/Female 13/4 8/4
Type of CP (number) 
Unilateral/ Bilateral  13/4 10/2
  GMFCS       1.1±0.3 1.0±0 0.073
  GMFM    89.7±6.8  93.7±6.0 0.084
  FMS  6 6 1.0
Body weight     21.2±7.7  19.0±6.6 0.576
Dysport dose
 (IU/Kg/extremity)
  17.1±8.3   14.7±6.5  0.552
Values: mean±standard deviation, CP: Cerebral palsy, 
GMFCS: Gross motor function classification system, 
GMFM: Gross motor function measure, FMS: Functional 
mobility scale
p-value by Mann-Whitney U test
Table 2. Baseline Evaluation of Spasticity on Subjects 
Injection with
casting group 
(n=17)
Injection
only group
(n=12)
p-value
MTS
  R1 of ADF with KE  –5.7±3.8 –4.4±3.2 0.108
  R2 of ADF with KE  –0.5±4.6 0.7±5.2 0.441
  R1 of ADF with KF  2.3±6.4 3.8±5.5 0.448
  R2 of ADF with KF 6.0±5.5 8.9±5.4 0.373
MAS 1.7±0.3 1.5±0.4 0.901
PRS 7.9±3.5 8.2±3.4 0.895
Circumference (cm)  21.4±0.9 25.6±4.5 0.074
Values are mean±standard deviation
MTS: Modified Tardieu scale, R1: Degree of while fast 
stretch, R2: Degree of while slow passive stretch, ADF: 
Ankle dorsifl  exion, KE: Knee extension, KF: Knee fl  exion, 
MAS: Modified Ashworth scale, PRS: Physician’s rating 
scale
p-value by Mann-Whitney U test
Table 3. Changes on Botulinum Toxin A Injection with Casting Group (n=17)
Baseline  Post inj 3 wks   Post inj 6 wks Post inj 12 wks p-value 
MTS
  R1 of ADF with KE  –5.7±3.8    –1.3±3.2
†    0.7±1.0
‡,¶    1.0±2.1
§ <0.01* 
  R2 of ADF with KE  –0.5±4.6      4.0±7.1
†    8.7±4.1
‡,¶    9.0±3.4
§ <0.01* 
  R1 of ADF with KF  2.3±6.4     5.2±4.5
†    7.5±3.0
‡,¶    7.3±3.0
§      0.012* 
  R2 of ADF with KF  6.0±5.5      9.8±8.0
†  14.5±6.1
‡,¶  15.9±4.2
§ <0.01* 
MAS  1.7±0.3      1.3±0.3
†     1.2±0.7
‡,¶     1.2±0.3
§      0.001* 
PRS 7.9±3.5   10.1±3.6
† 11.3±2.4
‡   11.3±2.4
§     0.001*
Cir. (cm)  21.4±0.9  20.9±1.5 20.5±1.8
‡ 19.7±2.0 <0.01* 
Values: mean±standard deviation
MTS: Modified Tardieu scale, R1: Spastic catch, R2: Passive range of motion, ADF: Ankle dorsiflexion, KE: Knee 
extension, KF: Knee fl  exion, MAS: Modifi  ed Ashworth scale, Cir: Circumference
*p<0.05 by Freidman test, Post hoc test, 
†p<0.0083 signifi  cant diff  erence between baseline and post injection 3 wks, 
‡p<0.0083 signifi  cant diff  erence between baseline and post injection 6 wks, 
§p<0.0083 signifi  cant diff  erence between 
baseline and post injection 12 wks, 
¶p<0.0083 signifi  cant diff  erence between post injection 3 wks and 6 wksSook Joung Lee, et al.
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increase in R1 was greater than in R2 in weeks 3 and 6. To 
determine the difference between BTX-A injection and 
casting treatment, the ankle joint angle before treatment 
was compared to 1) ankle joint angle 3 weeks after BTX-A 
injection, and 2) ankle joint angle 6 weeks after casting 
in the injection with casting group. No signifi  cant change 
was found in ankle joint angles before and 3 weeks after 
treatment in both R1 and R2. However, R2 change before 
and 6 weeks after treatment in the injection with casting 
group was signifi  cantly greater than in the injection only 
group (Fig. 3).
  MAS, used to evaluate spasticity of the ankle joint, 
decreased for 12 weeks in the injection with casting 
group. In the injection only group, however, MAS 
decreased for 6 weeks, but showed an increase on the 
12th week. PRS, used to measure gait pattern improved 
significantly in both groups after BTX-A injection. Also, 
in the injection with casting group, PRS improved after 
serial casting (Tables 3, 4).
  Th   ree patients (11.5%) experienced heel pressure ulcers 
due to casting and had to stop treatment. All 3 patients 
suffered from Grade II pressure ulcers; 1 patient did 
Table 4. Changes on Botulinum Toxin A Injection Only Group (n=12)
Baseline  Post inj 3 wks   Post inj 6 wks Post inj 12 wks p-value 
MTS
  R1 of ADF with KE –4.4±3.2    0.6±5.3
†    1.8±3.8
‡,¶   1.1±2.5
§ <0.01* 
  R2 of ADF with KE    0.7±5.2    4.8±7.6
†   6.2±6.4
‡   5.8±3.7
§ <0.01* 
  R1 of ADF with KF    3.8±5.5   7.4±8.0   8.9±7.7   7.8±6.2   0.448 
  R2 of ADF with KF   8.9±5.4  12.4±8.5
† 14.2±6.9
‡  13.8±4.2
§   0.02* 
MAS    1.5±0.4   1.1±0.6  1.0±0.7    1.1±0.2  0.07 
PRS    8.2±3.4   10.7±2.7
†  10.7±2.7
‡  10.3±3.5
§   0.03*
Cir. (cm)  25.6±4.5  25.0±6.4  24.9±5.7  24.7±4.6     0.533 
Values: mean ± standard deviation
MTS: Modified Tardieu scale, R1: Spastic catch, R2: Passive range of motion, ADF: Ankle dorsiflexion, KE: Knee 
extension, KF: Knee fl  exion, MAS: Modifi  ed Ashworth scale, PRS: Physician’s rating scale 
*p<0.05 by Freidman test, Post hoc test, 
†p<0.0083 signifi  cant diff  erence between baseline and post injection 3 wks, 
‡p<0.0083 signifi  cant diff  erence between baseline and post injection 6 wks, 
§p<0.0083 signifi  cant diff  erence between 
baseline and post injection 12 wks, 
¶p<0.0083 signifi  cant diff  erence between post injection 3 wks and 6 wks
Fig. 2. Changes of dynamic component in both groups, (A) Changes in Botulinum toxin A injection with casting group. (B) 
Changes in Botulinum toxin A injection group 
*p<0.05 by Freidman test, Post hoc test, 
†p<0.0083 signifi  cant diff  erence between baseline and post injection 3 wks, 
‡p<0.0083 
signifi  cant diff  erence between baseline and post injection 6 wks, 
§p<0.0083 signifi  cant diff  erence between baseline and post 
injection 12 wks, 
¶p<0.0083 signifi  cant diff  erence between post injection 3 wks and 6 wks.Botulinum Toxin Type A Injection with Serial Casting
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not express discomfort, but pressure ulcers were found 
during a weekly cast change, and the patient had to stop 
treatment. The other 2 patients expressed discomfort 
after receiving casting, and refused to put weight on the 
leg with the cast. Therefore, these patients’ casts were 
removed within a week, and pressure ulcers were found. 
No other skin problems were found, including contact 
dermatitis due to Stockinette. A cotton roll, fibroglass 
walking cast was used for casting. Most patients who 
received casting experienced calf muscle atrophy. When 
calf measurements of the patients in the injection with 
casting group were taken 12 weeks after injection, the 
results showed a −1.7±1.9 cm change compared to the 
measurements taken at the beginning of treatment. Th  e 
change was relatively large compared to the results from 
the injection only group (−1.0±1.2), and was statistically 
signifi  cant (p <0.01).
DISCUSSION
  Many studies on BTX-A injection and serial casting as a 
treatment for equinus gait have been conducted (Table 
5). From the late 1990s to 2000, after comparing BTX-A 
injection and casting treatment for 2 to 3 months, Corry 
et al.
7, Flett et al.
8, Houltram et al.
9 published studies 
arguing that greater changes in the of ankle joint angles 
were observed and eff  ects of the treatment lasted longer 
when patients received BTX-A injection rather than 
casting.
  From the early 2000s, studies were conducted in which 
both treatments were used. Booth et al.
10 compared 2 
groups: 1) the first group received casting every week, 
7-10 days after BTX-A injection, until the ankle dorsifl  ex 
angle was 20
o, 2) the second group received casting every 
week until the ankle dorsiflex angle was 20
o. Results 
showed that it took a relatively shorter amount of time for 
the patients in the fi  rst group to have their ankle dorsifl  ex 
angle become 20
o, and their ankle joint conditions 
improved faster. Bottos et al.
16 and Park et al.
21 compared 
2 groups: 1) the fi  rst group only received BTX-A injection, 
2) the second group was put in a cast for 3 weeks after 
BTX-A injection. The second group showed greater 
reduction in spasticity and greater increase in walking 
speed.
  However, Kay et al.
11 argued that casting is more eff  ective 
than BTX-A injection in improving ankle angle. Robert 
et al. compared 2 groups: 1) the first group received 
casting every 2 weeks, 1 to 3 weeks after injection, until 
the ankle dorsiflex angle was 5
o, 2) the second group 
only received casting every 2 weeks, until the ankle 
dorsiflex angle was 5
o. The changes in the ankle joint 
angles and spasticity in the second group were greater 
in the 12
th month, compared to the changes seen in the 
injection with casting group. Th   e results also showed that 
spasticity recurred in months 6, 9, and 12 in the injection 
with casting group. Glanzman et al.
15 compared the 
eff  ects of 3 diff  erent treatments in a chart analysis study: 
1) BTX-A injection, 2) casting, 3) BTX-A injection with 
casting. Results showed that casting was more effective 
than BTX-A injection, and that there was no difference 
Fig. 3. Changes between post & pre-injection, (A) Changes between post-injection 3 weeks and pre-injection, (B) Changes 
between post-injection 6 weeks and pre-injection. Th   e changes were larger for ΔR2 degree in the injection with cast group than 
the injection only group. *p<0.05 by Mann-Whitney U test. Sook Joung Lee, et al.
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Table 5. Comparison of Recent Studies 
Study Sample size Design Method Conclusion summary
Corry et al., 1998
7 n=20 RCT BTX injection 
 vs. casting
BTX-A effi   cacy was similar to that of
 serial casting. Th   ere were fewer side
 eff  ects in the BTX-A group.
Fllett et al., 1999
8 n=20 RCT BTX injection 
 vs. casting
BTX-A injections were of similar
 effi   cacy to serial fi  xed plaster casting
 in improving dynamic calf tightness in
 ambulant children. Parents consistently
 favored BTX-A and highlighted the
 inconvenience of serial casting.
Houltram et al., 
 2001
9
Combined 
several 
articles
Evidence
based 
economic
evaluation
BTX injection 
 vs. casting
BTX-A can be considered a valuable
 and cost-eff  ective treatment in the 
conservative management of equinus
 due to calf spasticity in children with
 cerebral palsy.
Booth et al., 2003
10 n=30 Retrospective 
review of
record
BTX vs. BTX injection
 with serial casting,
 casting started 7-10 days
 after injection, changed
 weekly until ADF>20°
Using serial casting in conjunction with
 BTX-A may achieve range of motion
 goals in less time than serial casting
 alone. 
Bottos et al., 2003
16 n=10 RCT BTX vs. BTX injection
 with casting, casting
 applied immediately
 after injection for 3
 weeks, total 1 times
BTX-A reduces spasticity and improves 
 functional performance in standing 
 and walking; association with casting 
 provides more marked and enduring 
 results.
Kay et al., 2004
11 n=23 RCT BTX with serial casting
 vs. serial casting; casting
 started 1-3 weeks after
 injection, changed every
 2 weeks until ADF>5°
Serial casting alone is preferable for the 
 treatment of fi  xed equines contractures 
 in children with cerebral palsy.
Glanzman et al.,
 2004
15
n=55 Retrospective 
analysis
BTX vs. casting vs.
 combined  treatment
Casting demonstrated a signifi  cantly 
 more robust impact on range of motion 
 than BTX-A alone.
Desloovere et al.,
 2001
14
n=34 RCT Casting after BTX
 injection vs. casting
 before injection
More pronounced benefi  ts, mainly in 
 the proximal joints, were seen for the 
 children who were casted after 
 injections as compared to the children 
 who were casted before injections.
Newman et al.,
 2007
17
n=12 RCT Delayed (4 weeks later)
 vs. immediate (same
 day) serial casting after
 BTX injection
Th   ere is a clear benefi  t in delaying serial 
 casting after the injection of botulinum 
 toxin in the recurrence of spasticity at 
 the gastrocnemius.
Park et al., 2010
21 n=38 RCT Serial casting after BTX
 injection vs. BTX,
 casting started
 immediately after
 injection, changed
 weekly for 3 times
Serial casting application after BTX-A 
 injection can enhance the benefi  ts of 
 BTX-A injection in children with 
 cerebral palsy.
BTX: Botulinum toxin, RCT: Randomized controlled trial, ADF: Ankle dorsifl  exionBotulinum Toxin Type A Injection with Serial Casting
351 www.e-arm.org
between casting and injection with casting. Therefore, 
Glanzman et al. argued that casting was more effective 
than BTX-A injection for improving ankle dorsifl  ex angle. 
Fifty-five patients participated in the study, and it was 
a retrospective chart analysis, but there was no control 
group and the study was not blinded. Therefore, only 
changes in ankle joint angles were assessed and whether 
there was improvement in function is unclear.
  There have been many studies in which various 
combinations of injection and casting were tested. 
Desloovere et al.
14 compared an injection after casting 
group, and a casting after injection group, and concluded 
that casting after injection was more eff  ective.
  Newman et al.
17 compared 2 groups: 1) the first group 
received serial casting immediately after injection, 2) the 
second group received casting 4 weeks after injection. 
Six months later, the ankle angle in the second group 
improved significantly and none of the patients in the 
group expressed pain, whereas children in the fi  rst group 
expressed pain.
  Although BTX-A injection and serial casting treatment 
have been studied for a while, there are still no guide-
lines. Therefore, even though the effectiveness of the 
treat  ment was shown in several studies conducted 
abroad, not many studies regarding side effects of 
casting have been published in Korea. Consequently, 
researchers adopted methods considered most eff  ective: 
1) researchers perform serial casting 3 weeks after BTX-A 
injection, 2) patients receive casting every week for 3 
weeks, 3) ankles are put in maximum dorsifl  exion during 
recasting, 4) thigh measurements are taken before and 
after treatment to determine side effects, 5) patients 
receive weekly serial casting and are checked for pressure 
ulcers or skin problems. 
  In this study, the patients were divided into a BTX-A 
injection only group, and an injection with casting group. 
Results showed greater improvement in the ankle joint 
angle, and greater reduction in spasticity in the injection 
with casting group, which is consistent with studies 
conducted earlier.
10,15-17
  We assume that the injection with casting group showed 
improvement because it was easier to induce ankle joint 
angle change through casting when BTX-A injection 
was in effect. Also, casting could have caused larger 
and longer lasting changes in the ankle joint angle. R1 
increased more than R2 3 weeks after BTX-A injection, 
therefore the dynamic component decreased. R1 
indicates the degree of muscle spasticity,
22 therefore the 
results obtained are consistent with other studies.
19,23,24 
However, 3 to 6 weeks after casting in the injection with 
casting group, R2
22 increased more than R1, and the 
dynamic component also increased (Figs. 2, 3). This 
shows that casting maintains muscles in tonic stretch to 
increase elasticity and to eff  ect changes in characteristics 
of muscle-ligament parts.
5
  Other studies rarely mention BTX-A and casting 
complications. One of the side effects following casting 
was the loss of calf muscles. Patients in casts were 
encouraged to put weight on their legs wearing splints, 
but not enough weight must have been applied. Parents/
caretakers also said that patients either refused to walk 
after casting, or used the leg without the cast to walk. 
We assume that 3 weeks of casting inhibited muscle 
contraction and therefore caused muscle atrophy. 
To enhance the effect of treatment and to minimize 
muscle atrophy, patients must perform weight bearing 
and isometric exercises. Other side effects include 
pressure ulcers, and 3 patients participating in this study 
experienced pressure ulcers, and therefore could not 
receive casting for 3 weeks and had to stop treatment. 
These 3 patients were children with cerebral palsy who 
had linguistic problems and difficulties expressing 
themselves. Therefore, patients must be checked for 
disabilities, such as linguistic problems and intellectual 
disabilities.
  We recommended casting to 72 patients over 9 months, 
but only 26 children received casting. We assume not 
many children participated in the study because most 
patients were school aged children, and leg casts might 
slow down movements and cause bullying. Also, because 
warm weather from late spring to early autumn could 
cause skin problems such as sweating, eczema, and 
pressure ulcers, studies were usually conducted in the 
winter. 
CONCLUSION
  Compared to the injection only group, the ankle joint 
angles improved and lasted longer in the injection with 
casting group. Also, MTS showed that BTX-A injection 
and casting aff  ected R1 and R2 respectively, therefore the 
treatments contributed in diff  erent ways to improve ankle Sook Joung Lee, et al.
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joint conditions. We recommend BTX-A injection with 
casting when treating equinus gait, but side eff  ects must 
be taken into consideration. Participants must be chosen 
carefully, checked for skin problems during serial casting, 
and perform weight bearing and isometric exercises.
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